Tirzepatide Weight Loss Clinics in the United States

What Is Tirzepatide?

Tirzepatide is an FDA-approved dual GIP and GLP-1 receptor agonist - the first of its kind. Sold as Mounjaro for type 2 diabetes and Zepbound for weight management, it outperforms semaglutide in head-to-head weight loss trials.

By activating both GIP and GLP-1 pathways simultaneously, tirzepatide produces greater appetite suppression and metabolic improvements than single-agonist GLP-1 drugs. Clinical trials showed average weight loss of 20-22% of body weight over 72 weeks - the highest of any approved weight loss medication.

It is administered via weekly subcutaneous injection and requires physician supervision with periodic monitoring.

Who Considers Tirzepatide?

• Adults with obesity (BMI 30+) or overweight (BMI 27+) with a weight-related condition
• People with type 2 diabetes, especially those who did not achieve goals on GLP-1 therapy alone
• Patients seeking maximum weight loss under physician oversight
• Those with metabolic syndrome, insulin resistance, or NAFLD

What to Expect at a Consultation

Consultations for tirzepatide follow a similar pattern to other GLP-1 medications: medical history review, weight and metabolic assessment, and discussion of previous weight management attempts. Physicians typically start at a low dose (2.5mg) and titrate up over several months. Many clinics offer telehealth-first access with medication shipped directly. Regular follow-ups track weight, side effects, and metabolic markers.